Human Papillomavirus Vaccination After COVID-19.
JNCI Cancer Spectr
; 5(2): pkab011, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1123321
ABSTRACT
The current global novel coronavirus disease 2019 (COVID-19) pandemic threatens to derail the uptake of human papillomavirus (HPV) vaccination in low- and lower-middle income countries with major disruptions to routine immunization and the introduction of new vaccines delayed. This has a major impact on the World Health Organization cervical cancer elimination strategy, where it is dependent on HPV vaccination as well as cervical cancer screening and treatment. We discuss current opportunities and barriers to achieve high uptake of HPV vaccination in low- and lower-middle income countries as well as the impact of COVID-19. Implementation of 4 key recommendations for HPV vaccination in low- and lower-middle income countries is needed increased global financial investment; improved vaccine supply and accelerated use of a single-dose schedule; education and social marketing; and adoption of universal school-based delivery. With the commitment of the global health community, the adoption of these strategies would underpin the effective elimination of cervical cancer.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Uterine Cervical Neoplasms
/
Vaccination
/
Papillomavirus Infections
/
Alphapapillomavirus
/
Papillomavirus Vaccines
/
COVID-19
Type of study:
Observational study
Topics:
Long Covid
/
Vaccines
Limits:
Female
/
Humans
Language:
English
Journal:
JNCI Cancer Spectr
Year:
2021
Document Type:
Article
Affiliation country:
Jncics
Similar
MEDLINE
...
LILACS
LIS